UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934
JULY 29, 2003
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 0-12666 87-0458888
(State or Other Jurisdiction of (Commission File No.) (I.R.S. Employer Identification No.)
Incorporation or Organization)
2500 WILCREST, 5TH FLOOR, HOUSTON, TEXAS 77042
(Address of principal executive offices and zip code)
(713) 780-4754
(Registrant's telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed from last report)
ITEM 5. OTHER EVENTS
On July 29, 2003 the Company issued a press release relating to its
clinical trials. The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. The reader is advised to read the press
release in its entirety.
[THE SIGNATURE PAGE FOLLOWS.]
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
ISOLAGEN, INC.
Date: July 29, 2003 By: /s/ Jeffrey W. Tomz
----------------------------
Chief Financial Officer
2
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press Release